Principal Financial Group Inc Selecta Biosciences Inc Transaction History

Principal Financial Group Inc

  • $162 Billion
  • Q1 2024

A detailed history of Principal Financial Group Inc transactions in Selecta Biosciences Inc stock. As of the latest transaction made, Principal Financial Group Inc holds 12,241 shares of SELB stock, worth $10,282. This represents 0.0% of its overall portfolio holdings.

Number of Shares
12,241
Previous 15,559 21.33%
Holding current value
$10,282
Previous $10,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 29, 2024
SELL
$0.62 - $0.85 $2,057 - $2,820
-3,318 Reduced 21.33%
12,241 $10,000
Q3 2023

Nov 02, 2023
BUY
$1.02 - $1.23 $2,926 - $3,528
2,869 Added 22.61%
15,559 $16,000
Q2 2023

Aug 07, 2023
BUY
$1.04 - $1.4 $13,197 - $17,766
12,690 New
12,690 $14,000
Q3 2022

Nov 09, 2022
SELL
$1.33 - $2.6 $62,422 - $122,028
-46,934 Reduced 63.62%
26,843 $44,000
Q2 2022

Aug 10, 2022
BUY
$0.67 - $1.4 $15,314 - $32,001
22,858 Added 44.89%
73,777 $97,000
Q1 2022

May 09, 2022
SELL
$1.23 - $3.31 $24,381 - $65,610
-19,822 Reduced 28.02%
50,919 $63,000
Q4 2021

Feb 09, 2022
SELL
$2.89 - $4.43 $253,204 - $388,130
-87,614 Reduced 55.33%
70,741 $231,000
Q3 2021

Nov 09, 2021
SELL
$3.36 - $4.62 $51,098 - $70,260
-15,208 Reduced 8.76%
158,355 $659,000
Q2 2021

Aug 10, 2021
BUY
$2.82 - $5.01 $220,061 - $390,960
78,036 Added 81.69%
173,563 $725,000
Q1 2021

May 10, 2021
BUY
$2.92 - $5.07 $21,318 - $37,016
7,301 Added 8.28%
95,527 $432,000
Q4 2020

Feb 08, 2021
BUY
$1.64 - $3.42 $144,690 - $301,732
88,226 New
88,226 $267,000

Others Institutions Holding SELB

# of Institutions
68
Shares Held
41.4M
Call Options Held
16.8K
Put Options Held
0
View Full List

About SELECTA BIOSCIENCES INC

SELB Quotes by TradingView
  • Ticker SELB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 152,712,992
  • Market Cap $128M
  • Description
  • Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in preclinical stage to improve the treatment of methylmalonic acidemia. I...
More about SELB
Track This Portfolio

Track Principal Financial Group Inc Portfolio

Follow Principal Financial Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Principal Financial Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Principal Financial Group Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email